BioSpace News Archive

BioCapital

REGENXBIO and Neurimmune Announce Collaboration to Develop Vectorized Antibodies for the Treatment of Neurodegenerative Diseases

REGENXBIO Inc. (Nasdaq: RGNX), today announced an exclusive license, development and commercialization agreement to discover and develop novel AAV gene therapies using NAV Vectors

July 24, 2019
·
8 min read
Business

Varian Reports Results for Third Quarter of Fiscal Year 2019

Varian, Inc.(NYSE: VAR) today announced its third quarter fiscal year 2019 results.

July 24, 2019
·
19 min read
Drug Development

Bristol-Myers Squibb Announces CheckMate -227 Part 1a Meets Co-Primary Endpoint of Overall Survival

Bristol-Myers Squibb Company (NYSE: BMY) today announced that Part 1a of the Phase 3 CheckMate -227 trial evaluating Opdivo® (nivolumab) plus low-dose Yervoy® (ipilimumab) met the co-primary endpoint of overall survival (OS), demonstrating a superior benefit versus chemotherapy in first-line non-small cell lung cancer (NSCLC) patients whose tumors express PD-L1 ≥1%.

July 24, 2019
·
35 min read
Biotech Beach

Stratify Genomics Announces Additional $2.2M Seed Series Funding

Stratify Genomics, a pioneer in genetic testing for cancer risk, is pleased to announce it has successfully raised a third Seed Series investment of $2.2 million from angel investors.

July 24, 2019
·
1 min read
Acerus Congratulates US Partner Aytu Bioscience on Listing of NATESTO® on National Pharmacy Benefit Manager’s Formulary

Acerus Pharmaceuticals Corporation announced that NATESTO® is now on formulary and covered nationwide by a leading national pharmacy benefit manager in the United States.

July 24, 2019
·
3 min read
Business

Genomma Lab Internacional Reports Second Quarter 2019 Results

Genomma Lab Internacional, S.A.B. de C.V. announced its results for the second quarter ended June 30, 2019.

July 24, 2019
·
4 min read
Drug Development

First Patient Dosed in Sintilimab and Anti-VEGF Monoclonal Antibody IBI305 with Chemotherapy in Patients with EGFR-mutant Non-squamous NSCLC who have Progressed from Prior EGFR-TKI Treatment

Innovent Biologics, Inc. announced that the first patient has been dosed in ORIENT-31, a trial that evaluates Tyvyt®, a fully human anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody co-developed with Eli Lilly and Company, and IBI305, a recombinant humanized anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody

July 24, 2019
·
7 min read
Deals

Castle Biosciences Announces Pricing of Initial Public Offering at $16.00 per share.

Castle Biosciences, Inc. announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a price to the public of $16.00 per share.

July 24, 2019
·
2 min read
Deals

KPTI INVESTOR ALERT: Hagens Berman Alerts Investors in Karyopharm Therapeutics (KPTI) Public Offerings to Possible Disclosure Violations

Hagens Berman Sobol Shapiro LLP alerts investors in Karyopharm Therapeutics Inc.'s April 28, 2017 and May 7, 2018 public offerings to the firm’s investigation into possible securities law violations.

July 24, 2019
·
2 min read
FDA

BAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA

BAQSIMI is expected to be available in U.S. pharmacies within one month

July 24, 2019
·
16 min read